Human Leukocyte Antigen (HLA) Antibody Screening Global Market Report 2026

The human leukocyte antigen (HLA) antibody screening market size has grown strongly in recent years. It will grow from $0.98 billion in 2025 to $1.06 billion in 2026 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to rising number of organ transplant procedures, increasing incidence of end-stage organ failure, growing awareness of transplant rejection risks, expansion of transfusion medicine practices, technological advancements in immunoassay platforms.

The human leukocyte antigen (HLA) antibody screening market size is expected to see strong growth in the next few years. It will grow to $1.47 billion in 2030 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to increasing demand for precision transplant matching, growing adoption of multiplex bead-based assays, rising investments in transplant immunology research, expansion of transplant programs in emerging markets, technological innovation in automated hla antibody screening systems. Major trends in the forecast period include increasing adoption of single antigen bead assays for enhanced sensitivity, rising demand for comprehensive pre-transplant immunological risk assessment, growing use of high-throughput flow cytometry in hla screening, expansion of post-transplant antibody monitoring protocols, increasing standardization of hla antibody detection methods.

The increasing rates of organ transplantation are anticipated to drive the expansion of the HLA antibody screening market in the coming years. Organ transplantation rates indicate the number of organ transplant procedures carried out within a particular population over a defined period, typically measured annually or per million individuals. This growth in transplantation procedures is mainly due to the rising prevalence of chronic and end-stage diseases; as more patients progress to organ failure, the demand for organ replacement therapies correspondingly rises. HLA antibody screening enhances the success of organ transplants by ensuring improved donor-recipient compatibility prior to surgery, thereby reducing the risk of immune-mediated rejection, minimizing graft loss and complications, enhancing long-term transplant outcomes, and allowing more efficient use of available donor organs. For example, in January 2025, the Health Resources and Services Administration, a US Department of Health and Human Services agency, reported that lung transplants saw the largest proportional increase between 2023 and 2024, rising from 3,026 to 3,340 procedures, representing a 10.4% growth. Hence, the rising organ transplantation rates are fueling the growth of the HLA antibody screening market.

Leading companies operating in the HLA antibody screening market are focusing on developing next-generation HLA research tools to improve immune checkpoint research, antibody validation, and assay development accuracy. Next-generation HLA research tools comprise innovative recombinant reagents, multiplexed analytical platforms, and high-resolution molecular technologies that allow precise profiling of HLA molecules and their antibody interactions. For example, in November 2025, HLA Protein Technologies, a US-based biotechnology company, launched its sHLA-G Monomer and Tetramer Portfolio, a next-generation HLA research tool that supports high-fidelity checkpoint biology studies, target validation, and assay development. The portfolio provides structurally validated recombinant HLA-G reagents optimized for immune receptor interaction studies, facilitating enhanced characterization of HLA-associated antibodies and advancing applications in transplant immunology, oncology, and immune tolerance research.

In June 2023, Innobiochips, a France-based biotechnology company, entered into a technology licensing agreement with BAG Diagnostics to advance transplantation diagnostics by providing broader access to high-precision HLA antibody screening technologies. The collaboration is designed to reinforce Innobiochips’ presence in the transplantation diagnostics sector through the licensing and commercialization of BAG Diagnostics’ HLA antibody screening solutions, improving transplant compatibility testing. BAG Diagnostics is a Germany-based diagnostics company specializing in HLA typing and antibody screening assays for transplantation medicine.

Major companies operating in the human leukocyte antigen (HLA) antibody screening market are Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Becton Dickinson Company, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Grifols S A, Beckman Coulter Inc., Bio Rad Laboratories Inc., QIAGEN N V, Takara Bio Inc., Fujirebio Inc., CareDx Inc., Histogenetics LLC, Creative Biolabs Inc., Biofortuna Ltd., Stanford Blood Center, GenDx B V, Omixon Biocomputing Ltd., BAG Diagnostics GmbH, Scisco Genetics Inc., TBG Diagnostics Ltd., American Red Cross.

North America was the largest region in the human leukocyte antigen (HLA) antibody screening market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human leukocyte antigen (HLA) antibody screening market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the human leukocyte antigen (HLA) antibody screening market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The human leukocyte antigen (HLA) antibody screening market consists of revenues earned by entities by providing services such as panel reactive antibody (PRA) testing, donor-specific antibody (DSA) identification, crossmatch testing, and antibody specificity and strength characterization. The market value includes the value of related goods sold by the service provider or included within the service offering. The human leukocyte antigen (HLA) antibody screening market also includes sales of automated ELISA processors, microplate washers, and fluorescence detection systems. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Human leukocyte antigen (HLA) antibody screening is a laboratory procedure used to detect antibodies targeting human leukocyte antigen (HLA) molecules in a person’s blood. These antibodies can develop from previous exposure to foreign HLA proteins through events such as blood transfusions, pregnancy, or organ transplants. HLA antibody screening helps evaluate immunological risk by identifying sensitization that could cause complications in transplant compatibility or immune-mediated reactions.

The primary technology types of human leukocyte antigen (HLA) antibody screening include enzyme-linked immunosorbent assay (ELISA), flow cytometry, luminex, and others. ELISA is a laboratory technique that detects and quantifies specific proteins, antigens, or antibodies in a sample using enzyme-linked antibodies that produce a measurable color change. Product types include reagents and kits, instruments, and software, targeting human leukocyte antigen class I antibodies, human leukocyte antigen class II antibodies, and non-human leukocyte antigen antibodies. Applications include pre-transplant screening, post-transplant monitoring, transfusion medicine, and research, serving hospitals and transplant centers, diagnostic laboratories, research institutes, and other end-users.

Tariffs on imported diagnostic reagents, bead-based assay kits, and specialized flow cytometry instruments are impacting the HLA antibody screening market by increasing procurement costs for hospitals and transplant laboratories. Segments such as reagents and kits and luminex-based technologies are particularly affected, especially in regions reliant on imported immunoassay systems including Asia-Pacific and Latin America. Higher tariffs may constrain laboratory budgets and delay equipment upgrades; however, they are also encouraging domestic manufacturing of assay kits and localized production of diagnostic instruments, fostering supply chain diversification and long-term regional self-sufficiency.

The human leukocyte antigen (HLA) antibody screening market research report is one of a series of new reports that provides human leukocyte antigen (HLA) antibody screening market statistics, including human leukocyte antigen (HLA) antibody screening industry global market size, regional shares, competitors with a human leukocyte antigen (HLA) antibody screening market share, detailed human leukocyte antigen (HLA) antibody screening market segments, market trends and opportunities, and any further data you may need to thrive in the human leukocyte antigen (HLA) antibody screening industry. This human leukocyte antigen (HLA) antibody screening market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.